Research Analysis · Health & function
Low-dose CT reduced lung-cancer mortality in selected high-risk smokers
NLST found fewer lung-cancer deaths with three annual low-dose CT screens than with chest radiography in selected current and former heavy smokers. The benefit came with many positive results that were false positives under the trial definition.
By Lois Rune
Published August 24, 2026 · Updated August 24, 2026 · AI-assistance disclosure
Evidence scope
Human lung-cancer mortality · large randomized screening trial
A mortality benefit in a narrowly defined high-risk population
The original NLST analysis reported 247 versus 309 lung-cancer deaths per 100,000 person-years, a 20% relative reduction with low-dose CT. It did not test never-smokers or the general population.
Who and what was tested
53,454 adults age 55–74 with at least 30 pack-years who currently smoked or had quit within 15 years; three annual screens.
What led
Lower lung-cancer mortality versus chest radiography in the selected trial population.
What remains unknown
The balance for people outside trial or current guideline eligibility, and the individual consequences of incidental findings, radiation and follow-up procedures.
The bottom line
NLST is strong randomized evidence that screening can reduce deaths from one cancer in a defined high-risk population. It is not evidence that CT screening benefits everyone, prevents smoking-related disease broadly, or extends lifespan.
What the randomized evidence found
In the original report, lung-cancer mortality was 247 deaths per 100,000 person-years with low-dose CT and 309 with chest radiography—a 20.0% relative reduction (95% CI 6.8%–26.7%).
With median 12.3-year follow-up, lung-cancer deaths were 1,147 versus 1,236 (RR 0.92; 95% CI 0.85–1.00). The all-cause mortality difference was 4.2 per 1,000 participants (95% CI −2.6 to 10.9), so a clear all-cause benefit was not demonstrated.
Benefit and harm travel together
Benefit measured
62 fewer lung-cancer deaths per 100,000 person-years in the original comparison.
Who was studied
Current or former heavy smokers age 55–74—not never-smokers or average-risk adults.
False positives
24.2% of CT screens were positive; 96.4% of positive results were false positives under the trial’s older definition.
Why screening results are easy to misread
Lead-time bias can make survival after diagnosis look longer because diagnosis happens earlier even if death does not. Length bias makes periodic screening more likely to find slower-growing disease. Overdiagnosis means finding disease that would never have caused symptoms or death.
A positive screen is not a cancer diagnosis. NLST’s definition and nodule-management era produced very high positive and false-positive rates; modern programs may classify findings differently, but follow-up scans and procedures remain part of the tradeoff.
Radiation exposure, incidental findings, invasive work-up and overdiagnosis belong beside the mortality result. The trial compared CT with chest radiography, not with every current screening pathway.
What this means for a screening decision
Current U.S. guidance recommends annual low-dose CT for certain adults age 50–80 with at least 20 pack-years who currently smoke or quit within 15 years, with stop conditions. Those criteria differ from NLST and require individual clinical assessment.
Screening can create both benefits and harms. Eligibility, prior testing, family and medical history, competing health risks, and personal preferences belong in a conversation with a qualified clinician.
Sources, funding and editorial method
Funding and conflicts. NLST was publicly supported by the National Cancer Institute and National Institutes of Health. The extended report lists ACRIN and NIH institutional grants and some author speaking, advisory or nonfinancial relationships involving organizations including LUNGevity, Siemens and Veracyte; the remaining authors reported nothing to disclose.
- NLST original mortality report
- NLST extended follow-up
- NLST registry record
- USPSTF lung-cancer screening recommendation
- Evidence review and prose drafting were separate. The article uses a frozen claim map with claim-by-claim source support.
- Primary population, outcomes, absolute context, limitations, adverse events, funding and conflicts were checked before publication.
- Lois Rune is responsible for the byline and final editorial framing. AI assisted with research organization and drafting under the published editorial disclosure.
- This is educational reporting, not personal medical advice.
More on screening outcomes and tradeoffs
An invitation trial separating incidence from demonstrated mortality benefit
A colonoscopy invitation lowered cancer incidence—not mortality at 13 years
In NordICC, inviting adults to one colonoscopy reduced colorectal-cancer incidence at 13 years. Colorectal-cancer mortality was not significantly lower, and participation limits what the invitation result says about completing screening.
Evidence scopeHuman cancer incidence and mortality · large randomized invitation trial
A second cancer-screening trial with false-positive and overdiagnosis tradeoffs
PSA screening lowered prostate-cancer mortality—and increased diagnoses
After 21 years in Rotterdam’s ERSPC section, repeated PSA-based screening reduced prostate-cancer mortality and metastatic disease in the primary age group, while producing substantially more prostate-cancer diagnoses.
Evidence scopeHuman prostate-cancer mortality and diagnosis · long randomized screening follow-up
A large prevention trial showing why all-cause outcomes matter
ASPREE did not lower cardiovascular events—and increased major bleeding
In selected older adults without cardiovascular disease, low-dose aspirin did not significantly reduce the trial’s cardiovascular composite. Major hemorrhage occurred more often.
Evidence scopeHuman cardiovascular and safety outcomes · large randomized trial
Article history
- : First published after three evidence-review passes and source/correction verification.
- Sources will be rechecked when guidance or the primary records change.